tbuckley/cabot-search huggingface dataset:
1150P Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Authors: B.L. Rapoport, R. Anderson, S. Siwele, H. Steel, L. Kwofie, M. Kgokolo, T. Smit, P. Meyer, N. Malinga
Journal: Annals of Oncology (2023)
1121P Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients
Authors: L. Hoeijmakers, P. Dimitriadis, A. van Vliet, J.M. Versluis, D. Peeper, C.U. Blank
Journal: Annals of Oncology (2023)
1141P Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma
Authors: E. Croce, A. Boutros, E.T. Tanda, F. Cecchi, L. Arecco, C. Genova, I. Baldelli, M. Lambertini, E. Raposio, L. Del Mastro, F. Spagnolo
Journal: Annals of Oncology (2023)
1137P Treatment strategies and survival outcomes in a nationwide, population-based cohort of patients with melanoma brain metastases: The role of planned shift in systemic therapy and postoperative stereotactic radiotherapy
Authors: S. Pedersen, E.L. Johansen, K. Højholt, M.H. Wett, A.M. Mogensen, S.K. Petersen, R.B. Friis, M. Donia, C.A. Haslund, H. Schmidt, L. Bastholt, I-M. Svane, E. Ellebæk
Journal: Annals of Oncology (2023)
1116P Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Authors: C. Boutros, D. Belkadi-Sadou, B. Archambaud, A. Vallet, A. Dutheil, A. Marchand, S. Roy, E. Routier, C. Robert
Journal: Annals of Oncology (2023)
1106P Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Authors: I. Pires da Silva, I. Li, S. Ugurel-Becker, P. Serra-Bellver, A. Andhale, H. Burnette, F. Aya, J. Conway, M. Carlino, A.M. Menzies, M. Weichenthal, P. Mohr, R. Gutzmer, A.M. Arance Fernandez, D. Johnson, P. Lorigan, D. Schadendorf, S. Lo, G.V. Long
Journal: Annals of Oncology (2023)
1131P Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Authors: M.F. Ribeiro, I. Hirsch, E.C. Koch, L. Mantle, T. Pimentel Muniz, M. Silveira Vilbert, K. Abdulalem, D.P. Arteaga Ceballos, S. Genta, P. Spiliopoulou, O. Vornicova, C. Fournier, E. Giovannetti, H. Krema, S. Saibil, A. Spreafico, M.O. Butler
Journal: Annals of Oncology (2023)
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Authors: F. Costa Svedman, M. Liapi, A. Chatzidionysiou, A. Månsson-Broberg, S. Egyhazi Brage
Journal: Annals of Oncology (2023)
1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Authors: M. Orloff, C. Watkins, R.D. Carvajal, A.N. Shoushtari, J.J. Sacco, M. Schlaak, J. Gama, M.O. Butler
Journal: Annals of Oncology (2023)
1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study
Authors: G-U. Grigoleit, H. Kluger, S. Thomas, J.A. Chesney, E. Domingo-Musibay, M.F. Sanmamed, T. Medina, M. Ziemer, E. Whitman, F. Graf Finckenstein, J. Chou, X. Wu, G. Sulur, W. Shi, A. Sarnaik
Journal: Annals of Oncology (2023)
1082O Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)
Authors: I.C. Glitza, S. Phillips, I. John, R.L. Bassett, R. Lin, M.L. Rohlfs, J. Richard, M. Iqbal, T. Hennegan, I.E. McCutcheon, S. Ferguson, B. O'Brien, S. Tummala, N. Guha-Thakurta, M. Debnam, H.A. Tawbi, E. Burton, M. Davies
Journal: Annals of Oncology (2023)
1051P Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial
Authors: S. Dalle, T.U. Marron, C. Robert, B. Aljabri, M.S. Nyakas, K. Bruins Slot, V. Sundvold, Ø. Rekdal, B. Sveinbjornsson, G. Currie
Journal: Annals of Oncology (2023)
1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Authors: I. Reijers, P. Dimitriadis, A.M. Menzies, E. Kapiteijn, A.A.M. Van der Veldt, K.P.M. Suijkerbuijk, G.A.P. Hospers, W. Van Houdt, R. Saw, A. Broeks, S. Cornelissen, L. Grijpink-Ongering, T. Pennington, A. Colebatch, B. van de Wiel, R. Scolyer, A.C.J. van Akkooi, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2023)
1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Authors: G.V. Long, F.S. Hodi, E.J. Lipson, D. Schadendorf, P.A. Ascierto, F.A. Medina Soto, M. Maio, M. Hernberg, J. Mackiewicz, S. Prey, M.K. Mujika Eizmendi, V.G. Atkinson, J.C. Hassel, G. Cinat, B. Ratto, S. Rodriguez, P.T. Wang, S. Dolfi, H.A. Tawbi
Journal: Annals of Oncology (2023)
1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Authors: M. Weichenthal, D. Schadendorf, L. Bastholt, I. Gavrilova, J.B.A.G. Haanen, J. Mangana, E. Espinosa, I-M. Svane, M. Wouters, E. Ellebæk, P. Mohr, I. Marques Rodas, N. Asher, R. Dummer, C. Gaudy Marqueste, F. Aya, H. Gogas, C. Lebbe, P. Rutkowski, P.A. Ascierto
Journal: Annals of Oncology (2023)
1097P Durable relapse-free survival in stage IV melanoma patients (pts) treated with neoadjuvant immune-checkpoint inhibitor (ICI) followed by local procedures
Authors: D. Belkadi-Sadou, A. Marchand, B. Archambaud, A. Cavalcanti, Y. Tao, L. Tselikas, S. Roy, E. Routier, C. Boutros, C. Robert
Journal: Annals of Oncology (2023)
1098P Anti-PD1-based neoadjuvant therapy in resectable stage III or IV melanoma patients: A systematic review and meta-analysis
Authors: T.M. Madeira, F. Cezar A Moraes, J.N. Priantti, E. Moisés de Lima Santiago, M.F. Ribeiro, M. Silveira Vilbert
Journal: Annals of Oncology (2023)
1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)
Authors: A. Prat, T. Pascual, M. Juan, L. Paz-Ares, E. Felip, E. Garralda, B. Gonzalez-farre, A.M. Arance Fernandez, J. Martin-Liberal, A. López, Y. Izarzugaza Peron, J. Garcia-Corbacho, C. Saura Manich, C. Hierro, E. Sanfeliu Torres, J.M. Cejalvo, F. Salvador, R. Mesia Nin, A. Cervantes, J. Tabernero
Journal: Annals of Oncology (2023)
1075TiP A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Authors: E.E. Dumbrava, E. Calvo, E. Garralda, M.H. Ryu, D-Y. Oh, L-Y. Bai, W. Chung, K.I. Rojas Laimito, O. Yildirim, S. Masciari, K. Kang, B. Buday, F. Rharbaoui, G. Abbadessa, V. Moreno Garcia
Journal: Annals of Oncology (2023)
1087MO A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study
Authors: J.C. Becker, B. Schilling, U. Leiter-Stoppke, L. Zimmer, J.C. Hassel, I. von Wasielewski, M. Ziemer, M. Fluck, F. Meier, A. Spillner, A. Gesierich, T. Eigentler, E. Livingstone, M. Albers, Y. Angela, R. Gutzmer
Journal: Annals of Oncology (2023)
1074TiP A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Authors: M. Gutierrez, E. Garralda, E. Calvo, M. van Dongen, F.A. Eskens, M. Finlay, F-Z. Menas, C. Zhu, M. Wu, H. GUILLEMIN-PAVEAU, G. Abbadessa, R. Perez, O. Yildirim, A. Naing
Journal: Annals of Oncology (2023)
1065P Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Authors: F. Pecci, G. Mentrasti, V. Cognigni, S. Lunetti, C. Cola, V.E. Mignini, L. Santamaria, V. Agostinelli, R. Chiarotti, C. De Filippis, M. Gualtieri, V. Lunerti, C. Copparoni, C. Felicetti, G. Belletti, V. Tarantino, A. Parisi, L. Cantini, M. Taus, R. Berardi
Journal: Annals of Oncology (2023)
1085O Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)
Authors: E. Burton, V. Honaker, D. Milton, I.C. Glitza, R. Amaria, S. Patel, A. Diab, M. Wong, J. Mcquade, C. Chung, J.S. Wefel, J. Li, M. Davies, H.A. Tawbi
Journal: Annals of Oncology (2023)
1105P First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Authors: K. Kozak, P. Teterycz, L. Galus, J. Mackiewicz, P. Brandys, B. Cybulska-Stopa, N. Kempa-Kaminska, M. Ziętek, J. Zubrowska, R. Dziura, P. Sobczuk, A.M. Czarnecka, P. Rutkowski
Journal: Annals of Oncology (2023)
1054P A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors
Authors: S. Qin, W. Tian, M. Li, H. Wei, L. Sun, Q. Xie, E. Lin, D. Xu, J. Tian, J. Chen, W. Lu, N. Gao, L. Chen, J. Duo, L. Ye, T. Cheng, Y. Sui, C. Klein, W. Chen
Journal: Annals of Oncology (2023)
1094P Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Authors: E. Burton, D. Milton, L. Simpson, M. Tetzlaff, I.C. Glitza, M.I. Ross, J.E. Gershenwald, J. Mcquade, M. Wong, S. Patel, A. Diab, M. Postow, C.E. Ariyan, J. Lee, S. Fisher, V. Prieto, M. Davies, H.A. Tawbi, J. Wargo, R. Amaria
Journal: Annals of Oncology (2023)
1050P Sensitization to immunotherapy through manipulation of tumor transcription by lurbinectedin
Authors: J.S. Russo-Cabrera, S. Ponce Aix, P. Cozar, A. Luengo, A.F. Navarro Mendivil, R. Bernabe Caro, M.E. Olmedo Garcia, J.M. Trigo Perez, J. Zugazagoitia, L. Paz-Ares, I. Otano Andres
Journal: Annals of Oncology (2023)
1083MO Brain metastases and survival evaluation in the SECOMBIT trial
Authors: P.A. Ascierto, M. Mandalà, P.F. Ferrucci, M. Guidoboni, P. Rutkowski, V. Ferraresi, A.M. Arance Fernandez, M. Guida, E. Maiello, H. Gogas, E. Richtig, M.T. Fierro, C. Lebbe, H. Helgadottir, I. Melero, G. Palmieri, D. Giannarelli, A.M. Grimaldi, R. Dummer, V. Chiarion Sileni
Journal: Annals of Oncology (2023)
1068P Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models
Authors: S. Cortellino, V. Quagliariello, G. Delfanti, None O. blazevits, C. Chiodoni, N. Maurea, A. Di Mauro, F. Tatangelo, F. Pisati, None A. shmahala, S. Lazzeri, V. Spagnolo, E. Visco, C. Tripodo, G. Casorati, P. Della Bona, V. Longo
Journal: Annals of Oncology (2023)
1063P Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
Authors: C. Tozzi, M. Ligero, A. Antolin, L.M. Atlagich, N. Staikoglou, K. Bernatowicz, M. Vieito Villar, G. Alonso, V. Galvao, I. Braña, A. Oberoi, O. Saavedra Santa Gadea, E. Muñoz Couselo, E. Garralda, R. Perez Lopez
Journal: Annals of Oncology (2023)
1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Authors: J. Rodon, M.F. Chaney, J. Cohen, T.K. Garyantes, J. Ishizuka, J.J. Lin, P. Lorusso, A. Mita, M. Mita, C. Muller, C. Natale, M. Orloff, K.P. Papadopoulos, S. Patel, A.N. Shoushtari
Journal: Annals of Oncology (2023)
1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Authors: J. Li, Y. Xu, A. Zang, Y. Gao, Q. Gao, Y. Zhang, D. Wang, J. Xu, Y. Yuan, H. Jiang, J. Ying, C. Shi, Y. Deng, J. Wang, T. Liu, Y. Huang, M. Shi, K. Wang, H. Hu, L. Shen
Journal: Annals of Oncology (2023)
1099P Long-term survival follow-up from the REDUCTOR trial: Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection
Authors: F.H. Burgers, S. Blankenstein, M. Rohaan, T. Seijkens, M. Klop, B. van der Hiel, M. Lahaye, B. van de Wiel, A. Sari, W. Van Houdt, A.C.J. van Akkooi, J.B.A.G. Haanen
Journal: Annals of Oncology (2023)
1072P DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Authors: S. Fellermeier-Kopf, A. Ioan-Facsinay, A. Imle, A.M. Diks, K.B. Nuermberger, L. Guelen, M. Köhne, M. Houtkamp, A. Toker, S.M. Burm, J. Gamse, C. Janaitis, D. Satijn, A. Muik, T. Ahmadi, Ö. Türeci, K. Kemper, U. Sahin, E. Breij
Journal: Annals of Oncology (2023)
1058P Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer
Authors: H-T. Wang, M-C. Lin, W-J. Lo, C-Y. Chen, S-T. Wang, C-F. Chiu, E-J. Bai, L-Y. Bai
Journal: Annals of Oncology (2023)
1060P Balance of CD36+ and CD16+ monocytes controls TLR-mediated cytokine release syndrome and MHC-dependent antitumor responses in EpCAM CAR T cell therapy for gastrointestinal cancers
Authors: D. Zhu, T. Luo, H. Wang, Z. Wu, B. Zhai, W. Fang
Journal: Annals of Oncology (2023)
1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Authors: R. Geva, M. Vieito Villar, None J. ramon, R. Perets, M. Pedregal, E. Corral de la Fuente, B. Doger de Spéville, E. Calvo, J. Bardina, E. Garralda, R.J. Brown, J. Gregor, S. Wu, D. Steinbach, S. Tsun-wen, Y. Cao, J. Lauring, V. Moreno Garcia
Journal: Annals of Oncology (2023)
1092P Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
Authors: M. Bloem, O.J. van Not, J.B.A.G. Haanen, C.U. Blank, M.J.B. Aarts, F.W.P.J. Van den Berkmortel, J.W. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, M. Stevense-den Boer, A.A.M. Van der Veldt, G. Vreugdenhil, H. Bonenkamp, M.J. Boers-Sonderen, W.A. Blokx, F. Van Den Eertwegh, K.P.M. Suijkerbuijk, M. Wouters
Journal: Annals of Oncology (2023)
1090P Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Authors: S. Martinez Recio, M.A. Molina Pérez, E. Muñoz Couselo, A.R. Sevillano Tripero, J. Martin-Liberal, M. Orrillo, A.M. Arance Fernandez, F. Aya Moreno, L.A. Fernández-Morales, M. Quindos Varela, R. Lesta, A. Barba Joaquín, I.G. Sullivan, M. Majem
Journal: Annals of Oncology (2023)
1069P Potential biomarkers for predicting severe immune-related adverse events during checkpoint immunotherapy: T Cell receptor and whole exome sequencing findings from a prospective multicenter study
Authors: None Z. hu, F. Zhang, None X. han, S. Cheng, Z. Yang, None Z. ma, L. Wang, None H. tao, S. Chen, Y. Hu
Journal: Annals of Oncology (2023)
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma
Authors: M.W. Lucas, E.A. Rozeman, J.M. Versluis, A.M. Menzies, H. Eriksson, B. van de Wiel, R. Scolyer, H.V. van Thienen, H. Mallo, M. Gonzalez, L. Landman, A. Torres Acosta, L. Grijpink-Ongering, J.B.A.G. Haanen, A.C.J. van Akkooi, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2023)
1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors
Authors: B. Tran, M. Millward, C. Lemech, S. Frentzas, D. Day, A. Latifi, J. Desai, P. Wabnitz, P. Kearney, A. Galkin
Journal: Annals of Oncology (2023)
1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma
Authors: J.S. Weber, W. Haque, S.N. Markovic, A.K.S. Salama, I. Mehmi, R.J. Sullivan, Y.G. Najjar, A.C.J. van Akkooi, A.M. Menzies, G.V. Long, A.M. Taylor, J.B.A.G. Haanen, L. Zijlker, K. Davis, S. Karanth, R. Shah, L. Connolly, D. Norton
Journal: Annals of Oncology (2023)
1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Authors: P.A. Ascierto, M. Del Vecchio, B. Merelli, H. Gogas, A.M. Arance Fernandez, S. Dalle, C.L. Cowey, M. Schenker, J.J. Grob, V. Chiarion Sileni, I. Marquez-Rodas, M.O. Butler, A.M. Di Giacomo, M. Pe Benito, R. Soomro, M. Askelson, J.S. Weber, J. Larkin
Journal: Annals of Oncology (2023)
1088MO A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up
Authors: N. Gross, D.M. Miller, N.I. Khushalani, V. Divi, E. Ruiz, E.J. Lipson, F. Meier, Y.B. Su, P.L. Swiecicki, J.L. Atlas, J.L. Geiger, A. Hauschild, J.H. Choe, B.G.M. Hughes, S-Y. Yoo, M.D. Mathias, H. Han, M.G. Fury, D. Rischin
Journal: Annals of Oncology (2023)
1062P Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Authors: C. Tournigand, A. Flechon, S. Oudard, E.B. Saada, D. Pouessel, C. Le Tourneau, P. Augereau, M. Beylot-Barry, J.J. Grob, B. Chibaudel, J-C. Soria, C. Simon, A. Lamrani-Ghaouti, F. Legrand, L. Gambotti, S. Chevret, T. André, A. Marabelle
Journal: Annals of Oncology (2023)
1066P Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent
Authors: V. Albarrán, P. Guerrero, C. Gonzalez Merino, C. García de Quevedo, A.M. Barrill Corpa, P. Sotoca-Rubio, V. Alia Navarro, P. Pérez de Aguado, J.C. Calvo, J. Moreno, J. Chamorro-Perez, D.I. Rosero Rodriguez, P. Alvarez Ballesteros, J.J. Serrano, C. Saavedra Serrano, Á. Ruiz, A. Gomez Rueda, A. Soria Rivas, P. Garrido Lopez, P. Gajate Borau
Journal: Annals of Oncology (2023)
1052P Phase-Ib trial of metformin combined with nivolumab for refractory/recurrent solid tumors
Authors: T. Kubo, H. Kato, S. Horiguchi, T. Ninomiya, T. Kozuki, A. Asagi, A. Takamoto, Y. Umeda, K. Kamikawa, M. Yoshida, U. Udono, K. Hotta, Y. Maeda, K. Kiura
Journal: Annals of Oncology (2023)

Conclusions:The results provide initial evidence of Temferon's potential to reprogram GBM TME and elicit T cell-mediated immune responses.
1042P INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Authors: A. Atmaca, D.W. Müller, T. Habibzada, M. Schaaf, J. Klagges, R. Eickhoff, E. Jäger, S-E. Al-Batran, T.O. Goetze
Journal: Annals of Oncology (2023)
1053P Tumor-restricted delivery of an immune-therapeutic payload by modified macrophages for the treatment of glioblastoma: The TEM-GBM STUDY (NCT03866109)
Authors: F. Ciceri, B. Gentner, A. CAPOTONDO, M. Eoli, E. Anghileri, F. Farina, Q.G. D'Alessandris, V. Ferla, A. Franzin, P. Ferroli, F. Gagliardi, F. Legnani, S. Mazzoleni, K. Mullen, A. Olivi, R. Pallini, M. Saini, L. Naldini, C. Russo, G. Finocchiaro
Journal: Annals of Oncology (2023)
1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
Authors: A.M. Di Giacomo, V. Chiarion Sileni, M. Del Vecchio, P.F. Ferrucci, M. Guida, P. Quaglino, M. Guidoboni, P. Marchetti, E. Simonetti, G. Amato, A. Covre, R. Camerini, L. Calabro, M. Valente, M. Mandalà, D. Giannarelli, M. Maio
Journal: Annals of Oncology (2023)
1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)
Authors: M. Mckean, B. Chmielowski, M.O. Butler, R. Carvajal, J. Rodon, M. Carlino, K.B. Kim, T. Wise-draper, S. Khan, A.K.S. Salama, J. Moser, J. Reeves, K.D. Wilner, M. Maurer, M. Abed, B. Mitchell, D. Beaupre, M. Orloff
Journal: Annals of Oncology (2023)
1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Authors: J. Yong Hong, B-Y. Ryoo, M. Chenard-Poirier, K. Almhanna, D.W-T. Lim, J. Samol, G. Abbadessa, R. Meng, S. Masciari, A. Kefsi, Y. Zhang, H. Guillemin-Paveau, B. Pasquier, L. Lepine, E.E. Dumbrava
Journal: Annals of Oncology (2023)
1049P Phase Ib/II trial of envafolimab, a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors
Authors: T. Liu, Y. Feng, X. Xu, X. Ren, J. Jia, H. Pan, B. Wang, B. Wu, X. Cao, J. Liu, Y. Yang, S. Xiao, L. Qin, D. Zhu, S. Xu, W. Huang
Journal: Annals of Oncology (2023)
1048P Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer
Authors: N. Kotecki, S. Rottey, E. Garralda, V. Galvao, M.J. De Miguel Luken, O. Saavedra Santa Gadea, V. Boni, J. Johnson, J.P. McNally, A. McEwen, S. Murphy, S. Singhal, N. Pandya
Journal: Annals of Oncology (2023)
1093P Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Authors: A. Tarhini, Z. Eroglu, E. Castellano, J.S. Zager, R.J. Gonzalez, A. Sarnaik, C.W. Cruse, D.B. De Aquino, E. Abraham, A. Richards, D. Kalos, Y.A. Chen, E. Browning, D. Canton, P-L. Chen, J.L. Messina, V.K. Sondak
Journal: Annals of Oncology (2023)
1061P Association of transcriptomic mapping of tumors with high expression of Tregs to identify surfaceome gene signatures with efficacy to check point inhibitors
Authors: M.D.M. Noblejas Lopez, E. García-Gil, P. Pérez Segura, P. Gancarski, L. Martín, A. Pandiella, B. Gyorffy, A. Ocana Fernandez
Journal: Annals of Oncology (2023)
1100P Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Authors: M. Joerger, S. Diem, N. Wyss, K-L. Koster, D. Hess, Y. Metaxas, M-C. Flynn, S. Aeppli, T.P. El Saadany, S. Mane, E. Hiendlmeyer, R.A.F. von Moos, L. Flatz
Journal: Annals of Oncology (2023)
927P Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Authors: B. Kubuschok, E. von der Heyde, D.A. Hahn, C. Langer, U. Bockmühl, H. Mueller-Huesmann, G. Klautke, P-S. Mauz, B. Reuter, J. von der Grün, D. Beutner, J. Büntzel, C-J. Busch, B.F. Tamaskovics, J. Riera Knorrenschild, M.K. Welslau, T.C. Gauler, D. Waldenberger, A. Dietz
Journal: Annals of Oncology (2023)
939P Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Authors: L. Xue, Y. Han, Q. Zhang, X. Li, M. Fang, L. Zhong, S. Wang, Y. Liu, S. Zhang, Y. Guo
Journal: Annals of Oncology (2023)
936P Triple oral metronomic chemotherapy (OMCT) versus physician choice chemotherapy after failure of platinum-based therapy in advanced head and neck squamous cell cancer (HNSCC): A phase III randomized open-label study
Authors: A. Kapoor, A. Gupta, B. Sansar, None A. singh, L. Kashyap, R. Kumari, A. Kumar, S. Nanda, A.R. Kapoor, A. Mukherji, A. Mishra, A. Pal, None B. bandekar, S.N. Singh, K. Vinayak, S. Dey, V.M. Patil, V. Noronha, S. Banavali, K. Prabhash
Journal: Annals of Oncology (2023)
928P Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Authors: Z. Vidales Sepulveda, M. Choulli, S. Fabrego, N. Pallares, N. Santos, S. Llop Serna, J. Brenes Castro, M. Plana Serrahima, C.M. Juarez Lozano, A. Brunet, M. Melero, O. Bermejo, E. Vilajosana, C. Godino, M. Oliva, L. Arribas
Journal: Annals of Oncology (2023)